Welcome to our dedicated page for Hydreight Tech news (Ticker: HYDTF), a resource for investors and traders seeking the latest updates and insights on Hydreight Tech stock.
Hydreight Technologies Inc. (HYDTF) regularly publishes news and corporate updates that reflect its role as a digital health and mobile clinic platform operating across all 50 U.S. states. Company announcements focus on platform expansion, treatment category launches, pharmacy and telehealth integrations, and operational milestones tied to its mobile clinical network and VSDHOne direct-to-consumer infrastructure.
Investors and observers following Hydreight’s news can expect coverage of financial and operational performance, such as revenue trends, product order volumes, and profitability metrics, as disclosed in quarterly updates. The company also reports on nurse network growth, license counts, and pharmacy order activity, which it uses as indicators of platform adoption and utilization across its ecosystem.
Hydreight’s news flow highlights developments in its multi-vertical healthcare model. Releases have described growth across categories including GLP-1 weight management, testosterone replacement therapy, peptides, NAD+ therapies, hair loss and skincare offerings, sexual health products, genetics and personalized genetic testing, and other wellness and longevity services. Additional updates cover expansions into at-home and preventive testing, such as the company’s entry into the at-home STI pre-screening market through an exclusive distribution agreement for rapid testing kits.
Corporate communications also address strategic initiatives, including enhancements to the VSDHOne platform, investments in modular architecture, pharmacy partnerships such as the stake in Perfect Scripts, and financing activities like convertible debenture offerings. Recognition in programs such as the Deloitte Technology Fast 500™ and the TSX Venture Exchange Top 50 is another recurring theme in Hydreight’s news.
For readers tracking HYDTF, the news page offers a centralized view of how Hydreight’s digital health infrastructure, mobile clinic network, and direct-to-consumer platforms are evolving over time. Regular updates provide context on the company’s operational metrics, treatment verticals, and strategic priorities within the U.S. digital health and wellness market.
Hydreight Technologies (OTC: HYDTF), a nationwide digital healthcare solutions provider, has successfully closed its oversubscribed private placement of unsecured convertible debentures, raising C$11.5 million including the full exercise of the over-allotment option.
The debentures, issued at C$1,000 each, will mature on September 4, 2028, carrying a 9.0% annual interest rate. They are convertible into common shares at C$4.06 per share, with interest payable semi-annually. The company maintains a forced conversion right if the stock trades above C$5.08 for 20 consecutive trading days.
CEO Shane Madden highlighted the company's recent achievement of profitability in Q2 and plans to use the proceeds for general corporate and working capital purposes to accelerate growth.
Hydreight Technologies (OTCQB:HYDTF), a mobile clinical network and medical platform, reported strong financial results for Q2 2025, marking its third consecutive quarter of profitability. The company achieved Q2 GAAP revenue of $5.38 million, up 31% year-over-year, and H1 2025 revenue of $9.92 million, representing a 33% increase.
Key performance metrics include Q2 Gross Margin of $1.93 million, Adjusted EBITDA of $182K, and GAAP Net Income of $50K. The company saw significant growth with a 77% increase in new nurse signups and 48% growth in pharmacy orders compared to Q2 2024.
Hydreight announced a strategic initiative to acquire a 5% equity stake in Perfect Scripts, LLC with an option to increase to 40%, and launched a C$10 Million Convertible Debenture Offering to support growth and M&A activities.
Hydreight Technologies (OTC: HYDTF) reported exceptional growth in its VSDHOne platform, with July orders reaching 35,642 SKUs - more than triple the projected 10,000 orders. The company is now targeting 55,000 SKU orders for August as it progresses toward its 2025 goal of 1.3 million total orders.
The company announced a strategic partnership with Perfect Scripts, gaining access to 503B outsourcing facilities for large-batch drug compounding. This integration enables nationwide API connectivity, automated prescription processing, and enhanced fulfillment capabilities. Additionally, Hydreight launched its Marketing Solutions subsidiary to provide turnkey marketing services to licensees and telehealth partners.
The company also announced the resignation of director Gabi Kabazo, effective August 8, 2025.
Hydreight Technologies (OTCQB: HYDTF), a telehealth and mobile medical services company, has been invited to participate in the Canaccord Genuity 45th Annual Growth Conference on August 12-13, 2025, in Boston. CEO Shane Madden and Board Chair Shafin Diamond Tejani will represent the company, discussing its growth strategy and new offerings.
The company will also host an investor webinar on July 24, 2025, focusing on the Perfect Scripts Acquisition. Notably, Hydreight reported 34% year-over-year revenue growth in Q1 and was recently ranked as the #56 fastest-growing company in North America on the 2024 Deloitte Technology Fast 500™.
Hydreight Technologies (OTCQB: HYDTF) has appointed Dr. Jeremy Roebuck as a director of the company, effective May 5, 2025. Dr. Roebuck, who has served on Hydreight's Board of Advisors since December 12, 2022, fills the vacancy created by the resignation of Alexandros Tzilios. Hydreight is a North American integrated mobile clinical network of nurses, doctors, and pharmacy distribution.
Dr. Roebuck expressed enthusiasm about joining the board at a crucial growth phase, highlighting the company's focus on delivering healthcare through a compliant, tech-enabled platform. He aims to contribute to scaling the platform and expanding Hydreight's presence across North America.
Hydreight Technologies reported strong financial results for Q4 and full-year 2024, marking significant growth milestones. The company achieved record revenue of $22.32 million in topline revenue (up 31% from 2023) and $16.04 million in GAAP revenue (up 39% from 2023).
Key achievements include reaching positive Adjusted EBITDA of $490K compared to -$1.38M in 2023, and positive cash flow from operations. The company's success was recognized through rankings on Deloitte's Technology Fast 50™ (#9 in Canada) and Fast 500™ (#56 in North America).
The mobile healthcare platform, operating across all 50 U.S. states, secured $5.4M in financing and expanded its services through VSDHOne platform. With a network of 3,000+ nurses and 200+ physicians serving 700+ cities, Hydreight's 2025 strategy focuses on scaling franchise partnerships, improving pharmacy margins, and launching new wellness categories.
Hydreight Technologies (TSXV: NURS) (OTCQB: HYDTF) announced its upcoming presentation at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025. CEO Shane Madden will present at 12:30 PM PST and host a Q&A session.
The company is building one of the largest mobile clinical networks in the US, offering services like weight loss treatments, hormone therapy, IV wellness, and at-home testing. Recent achievements include:
- Launch of Liraglutide and sublingual semaglutide on VSDHOne platform
- US partnership with 'Dr. Frank's Method' GLP-1 weight-loss brand serving 70,000+ clients
- Launch of $10M health accelerator fund for emerging healthcare brands
- Ranked #13 on Financial Times' Americas' Fastest Growing Companies 2025
- #56 on Deloitte's Technology Fast 500™
- Top 50 on TSX Venture 50